Moore DF - Search Results

1

Quantitative dysmorphology assessment in Fabry disease.

Ries M, Moore DF, Robinson CJ, Tifft CJ, Rosenbaum KN, Brady RO, Schiffmann R, Krasnewich D. Ries M, et al. Among authors: moore df. Genet Med. 2006 Feb;8(2):96-101. doi: 10.1097/01.gim.0000200950.25118.dd. Genet Med. 2006. PMID: 16481892 Free article.

2

Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.

Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW. Altarescu G, et al. Among authors: moore df. Blood Cells Mol Dis. 2000 Aug;26(4):285-90. doi: 10.1006/bcmd.2000.0310. Blood Cells Mol Dis. 2000. PMID: 11042029 Clinical Trial.

3

Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations.

Bonavita S, Schiffmann R, Moore DF, Frei K, Choi B, Patronas MD N, Virta A, Boespflüg-Tanguy O, Tedeschi G. Bonavita S, et al. Among authors: moore df. Neurology. 2001 Mar 27;56(6):785-8. doi: 10.1212/wnl.56.6.785. Neurology. 2001. PMID: 11274318

4

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Schiffmann R, et al. Among authors: moore df. JAMA. 2001 Jun 6;285(21):2743-9. doi: 10.1001/jama.285.21.2743. JAMA. 2001. PMID: 11386930 Clinical Trial.

5

Enhanced endothelium-dependent vasodilation in Fabry disease.

Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, Panza JA, Schiffmann R. Altarescu G, et al. Among authors: moore df. Stroke. 2001 Jul;32(7):1559-62. doi: 10.1161/01.str.32.7.1559. Stroke. 2001. PMID: 11441201 Free PMC article.

6

Selective arterial distribution of cerebral hyperperfusion in Fabry disease.

Moore DF, Herscovitch P, Schiffmann R. Moore DF, et al. J Neuroimaging. 2001 Jul;11(3):303-7. doi: 10.1111/j.1552-6569.2001.tb00051.x. J Neuroimaging. 2001. PMID: 11462299

7

Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.

Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P, Schiffmann R. Moore DF, et al. Circulation. 2001 Sep 25;104(13):1506-12. doi: 10.1161/hc3801.096352. Circulation. 2001. PMID: 11571244 Clinical Trial.

8

Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease.

Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, Brady RO, Sokoloff L, Moore DF. Itoh Y, et al. Among authors: moore df. J Neurochem. 2001 Dec;79(6):1217-24. doi: 10.1046/j.1471-4159.2001.00669.x. J Neurochem. 2001. PMID: 11752062 Free article.

9

Enzyme replacement therapy in Fabry disease.

Brady RO, Murray GJ, Moore DF, Schiffmann R. Brady RO, et al. Among authors: moore df. J Inherit Metab Dis. 2001;24 Suppl 2:18-24; discussion 11-2. doi: 10.1023/a:1012451320105. J Inherit Metab Dis. 2001. PMID: 11758675 Review.

10

Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.

Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, Arai AE, Brady RO, Schiffmann R. Moore DF, et al. Stroke. 2002 Feb;33(2):525-31. doi: 10.1161/hs0202.102601. Stroke. 2002. PMID: 11823664 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

279 results

Search Page